Holen Sie sich die Stockscreener-App
1.13
0.00%
0.00
Schlusskurs vom Vortag:
$1.13
Offen:
$1.17
24-Stunden-Volumen:
30,005
Relative Volume:
0.26
Marktkapitalisierung:
$25.32M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-58.20M
KGV:
-0.4341
EPS:
-2.603
Netto-Cashflow:
$-47.21M
1W Leistung:
-3.42%
1M Leistung:
-3.42%
6M Leistung:
+0.00%
1J Leistung:
-29.38%
1-Tages-Spanne:
$1.13
$1.1707
1-Wochen-Bereich:
$1.13
$1.22
52-Wochen-Spanne:
$0.9612
$1.78
Boundless Bio Inc Stock (BOLD) Company Profile
Firmenname
Boundless Bio Inc
Sektor
Branche
Telefon
(858) 766-9912
Adresse
10955 ALEXANDRIA WAY, SAN DIEGO
Compare BOLD vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BOLD
Boundless Bio Inc
|
1.13 | 25.32M | 0 | -58.20M | -47.21M | -2.603 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Boundless Bio Inc Stock (BOLD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-05-28 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-12-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-04-22 | Eingeleitet | Guggenheim | Buy |
| 2024-04-22 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-22 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Boundless Bio Inc Aktie (BOLD) Neueste Nachrichten
Stop Loss: Can Boundless Bio Inc ride the EV wave2026 Gainers & Long Hold Capital Preservation Plans - baoquankhu1.vn
BOLD Technical Analysis & Stock Price Forecast - Intellectia AI
Boundless Bio: Underestimated Biotech With First-In-Class EcDNA Targeted Kinesin Degrader - Seeking Alpha
Risks Report: Is Boundless Bio Inc stock a smart retirement pick2026 Price Momentum & Technical Confirmation Trade Alerts - baoquankhu1.vn
Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026 - The Manila Times
Inside a novel cancer drug aiming at ecDNA-positive, high-risk breast tumors - Stock Titan
Bear Alert: Can Boundless Bio Inc ride the EV waveInsider Buying & Weekly Momentum Picks - baoquankhu1.vn
Trend Review: Can Boundless Bio Inc maintain its current growth rateWeekly Trade Recap & Weekly High Return Stock Opportunities - baoquankhu1.vn
FORTY Should I Buy - Intellectia AI
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
Gains Report: What are the analyst revisions for Boundless Bio IncIs RAAQU stock a good investment in YEARWeekly Profit Report & Free Reliable Trade Execution Plans - baoquankhu1.vn
ASTI Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Boundless Bio posts smaller-than-expected Q4 loss - MSN
CVU Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
AHRT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Leerink reiterates Market Perform on Boundless Bio stock at $4 - Investing.com
Boundless Bio Reports Q4 and Full Year 2025 Financial Results, Highlights Progress of KOMODO-1 Clinical Trial and BBI-940 Program - Minichart
03268 Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
02400 Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
MGRD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Boundless Bio (BOLD) Posts First Revenue of $17.3M, Narrows Q4 Loss to $0.58/Share - AlphaStreet
Bold Biosciences 2025 10-K: ecDNA-Enabled Cancer Drug Development, Spyglass Platform & BBI-940 Kinesin Degrader Overview - Minichart
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - Bitget
Boundless Bio beats fourth quarter loss estimates By Investing.com - Investing.com Canada
Boundless Bio 10-K: $0 Revenue, $(58.2)M Net Loss, $(63.6)M Operating Loss - TradingView
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - GlobeNewswire Inc.
Exit Recap: Is Boundless Bio Inc stock a smart retirement pickEarnings Summary Report & AI Enhanced Trading Signals - baoquankhu1.vn
Breakouts Watch: Can MSPRI sustain its profitabilityMarket Performance Summary & Low Drawdown Momentum Ideas - baoquankhu1.vn
Boundless Bio to Participate in the Leerink Global Healthcare Conference - The Manila Times
Rezolute to Participate in the Citizens Life Sciences Conference - Bitget
Boundless Bio CEO to join Leerink healthcare fireside chat on March 11 - Stock Titan
Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight – Company AnnouncementFT.com - Financial Times
BOLD Should I Buy - Intellectia AI
BOLD SEC FilingsBOUNDLESS BIO INC 10-K, 10-Q, 8-K Forms - Stock Titan
MDCX PE Ratio & Valuation, Is MDCX Overvalued - Intellectia AI
Signal Recap: How liquid is AMBIWS stock2025 Retail Activity & AI Enhanced Trading Alerts - baoquankhu1.vn
Volume Recap: Can Broadstone Net Lease Inc outperform under higher oil prices2025 Geopolitical Influence & Weekly Setup with High ROI Potential - baoquankhu1.vn
Nextech exits Boundless Bio (NASDAQ: BOLD) with reported 0% ownership - Stock Titan
Will Boundless Bio Inc. stock continue dividend increasesInflation Watch & Consistent Income Trade Recommendations - mfd.ru
What Makes CTS (CTS) a New Buy Stock - Bitget
What Makes KB Financial (KB) a Strong Momentum Stock: Buy Now? - Bitget
Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's Why - Yahoo Finance
Boundless Bio Advances New Breast Cancer Drug BBI-940 Into First-in-Human Trial - TipRanks
FMR LLC Reduces Stake in Boundless Bio Inc: A Strategic Portfoli - GuruFocus
What is the long term forecast for Boundless Bio Inc. stockJuly 2025 Analyst Calls & Weekly High Conviction Ideas - mfd.ru
Investment Recap: What are the analyst revisions for Boundless Bio IncIs RAAQU stock a good investment in YEARJuly 2025 Chart Watch & Fast Exit Strategy with Risk Control - baoquankhu1.vn
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Fed Watch: Does Boundless Bio Inc have pricing powerWall Street Watch & Momentum Based Trading Signals - baoquankhu1.vn
Finance Watch: Four IPOs In One Week - Citeline News & Insights
Fund Flows: Can Boundless Bio Inc weather a recession2025 Investor Takeaways & AI Forecast Swing Trade Picks - baoquankhu1.vn
Boundless Bio CEO Zachary Hornby to Speak at Guggenheim Emerging Outlook: Biotech Summit 2026 - Quiver Quantitative
Finanzdaten der Boundless Bio Inc-Aktie (BOLD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):